United Therapeutics Gets FDA Clearance for Treprostinil SMI Trial in PH-COPD
Bitget2026/10/19 11:03- FDA cleared United Therapeutics to begin the phase 2 SUMMIT trial of treprostinil SMI in PH-COPD.
- The 16-week study will evaluate safety and tolerability in approximately 40 patients.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Susquehanna raises pre-earnings price targets for chip stocks: AMD (AMD.US), Qualcomm (QCOM.US), etc. receive upward revisions
Susquehanna has adjusted the target prices for chip stocks such as AMD, Intel, and Qualcomm.
Wedbush: Hard drive supply falls short of demand, Seagate (STX.US) and Western Digital (WDC.US) earnings reports may bring surprises
Wedbush reiterated its "outperform" ratings for Seagate and Western Digital, setting target prices at $1,000 and $650, respectively.
JPMorgan maintains Underweight rating on Nike (NKE.US): Deep in adjustment pains, performance pressures may persist until fiscal year 2028
Recently, JPMorgan released a U.S. equity research report on Nike. The research team participated in a face-to-face meeting with Nike's new CFO, Denton, updated profit assumptions based on management statements, and maintained an “underweight” investment rating on Nike.
Crypto prices
More
